---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-002050"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2024-04-02T23:59:59+00:00"
generated_at: "2026-06-04T03:31:38.278110+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Phio Pharmaceuticals reports 2023 net loss of $10.8M; cash at $8.5M with PH-762 trial progress

## Summary
- Net loss $10.8M ($5.20/share) vs $11.5M ($10.10/share) in 2022; R&D expenses down 10% to $6.3M.
- Cash at Dec 31, 2023: $8.5M, down from $11.8M at end of 2022.
- PH-762 Phase 1B: two patients completed treatment with no adverse events; four clinical sites under contract.
- Headcount reduced 36% and Marlborough lease not renewed; moved to 321 sq ft lab in Worcester.
- AgonOx study delayed; facility renovation expected to reopen May 2024; third patient infused in Nov 2023.

## SEC filing metadata
- accession: 0001683168-24-002050
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2024-04-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000168316824002050/0001683168-24-002050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000168316824002050/phio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-002050
- JSON: https://secwatch.observer/filing/0001683168-24-002050.json
- Plain text: https://secwatch.observer/filing/0001683168-24-002050.txt

## Key facts
- Earnings Releases
  Phio Pharmaceuticals Corp. reported the year ended December 31, 2023 results: net income $10.8 million, EPS $5.20 per share.
  - Period: the year ended December 31, 2023
  - Net income: $10.8 million
  - EPS: $5.20 per share
  - Result: reported results
  source text: Net loss was $10.8 million, or $5.20 per share, for the year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533040/000168316824002050/0001683168-24-002050-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.